Join us March 1-3, 2021 for Antibodies, Next-Generation Proteins & Bioconjugates Digital Week, a 3-day series of live educational webinars and downloadable resources providing the latest insights for accelerating the discovery and development of antibodies, bioconjugates and next-generation protein therapeutics to commercial success. To sponsor future digital week events, contact partners@informaconnectls.com.

DAY 1 – MONDAY, MARCH 1, 2021



Engineering Bispecific Antibodies as Therapeutics: Utilizing Intrinsic Heavy/Light Chain Pairing Preferences and Mitigating High Viscosity
9am EST / 2pm GMT/ 3pm CET 

Bispecific antibodies are coming of age as therapeutics with two currently marketed and 100+ more bispecifics in clinical development. This presentation will focus on addressing challenges that may assist in the development of some bispecific antibodies. Firstly, intrinsic antibody heavy/light chain pairing preference were investigated and then used to facilitate the efficient production of bispecific IgG in single host cells. Secondly, a mutational strategy was devised to mitigate high viscosity of some monospecific and bispecific antibodies that may facilitate subcutaneous delivery.

Speakers:

Paul J. Carter, Ph.D.
Genentech Fellow, Department of Antibody Engineering
Genentech

View More Details +

Writing the Future of Biologics using the Twist Biopharma Library of Libraries
10am EST / 3pm GMT/ 4pm CET

Utilizing its proprietary DNA technology to write synthetic libraries, Twist Biopharma provides end-to-end antibody discovery libraries including both (1) highly diverse synthetic naïve antibody phage display libraries and (2) target class specific antibody phage display libraries against difficult-to-drug targets.  In this talk, Aaron Sato, CSO, will present several POC data on each member of their Library of Libraries.  For some of the targets, the power of selecting multiple libraries against each target will be highlighted.

Speaker:

Aaron Sato. PhD
Chief Scientific Officer
Twist Bioscience

View More Details +

Rapid development and troubleshooting of robust microfluidic antibody-based therapeutic quantification for pharmacokinetic (PK) and toxicokinetic (TK) study support.
11am EST / 4pm GMT / 5pm CET

Discovery and development of monoclonal antibody (mAb) based therapeutics requires robust immunoassays for quantification to support pharmacokinetic and toxicokinetic studies. A flexible assay design is critical to support multiple species and programs with large numbers of samples, conditions and limited reagents. In this presentation, data from rapid development of microfluidic, flow-through Gyrolab immunoassays leveraging 1-hour assay times and unique software Viewer features for assay troubleshooting is presented. Advantages of these assays in COVID-19 related laboratory schedules and restrictions is also discussed.

Speaker:

Rob Durham, PhD
Director of Service and Scientific Support
Gyros Protein Technologies

View More Details +

Drug-like antibodies directly from selections: Specifica’s Generation 3 Antibody Library Platform
12pm EST / 5pm GMT/ 6pm CET

Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Much like small molecules, the inherent biophysical properties of antibodies affect the pharmacodynamics, pharmacokinetics, and manufacture of these molecules. Engineering potential leads with biological activities and biophysical properties suitable for therapeutic use can be extremely time consuming. The Specifica Generation 3 Antibody Library Platform is a validated new library architecture based on well-behaved therapeutic antibody scaffolds that are either FDA-approved on in advanced clinical trials. Five of the CDRs of these antibody drugs are replaced with replicated natural CDRs found in the human repertoire purged of known sequence liabilities - aggregation-prone motifs, glycosylation motifs, etc. While for HCDR3, the CDR with the greatest diversity, more than 100 million different HCDR3s are harvested from ≥10 healthy donors by PCR. Donors are used only once, ensuring exclusivity for each constructed library, and libraries are QC'd by next generation sequencing throughout, validating library diversity and quality.

This platform routinely yields antibodies with high affinities (20% subnanomolar and 40% between 1 nM and 10 nM); tremendous diversity (500-5000 different clonotypes differing by a mean Levenshtein distance of 20-40), and biophysical properties commensurate with the high developability standards required in therapeutic molecules (over 80% of antibodies have no measurable biophysical liabilities). When applied to the SARS-CoV-2 spike protein, antibodies as potent as the best from convalescent patients or immunization were obtained directly from the library (≥15 pM affinities and <1.5 ng/ml IC50 on live virus).

This is the first naive antibody library platform able to directly yield antibodies as potent as those generated by immunization.

Speaker:

Andrew Bradbury
Chief Scientific Officer
Specifica

View More Details +

DAY 2 – TUESDAY, MARCH 2, 2021



Targeted C’Dot-drug Conjugates (CDCs), a Novel Nanoparticle-based Platform for the Treatment of Cancer
9am EST / 2pm GMT / 3pm CET

Elucida is developing ultra-small, targeted nanoparticle drug conjugates (CDCs) capable of rapidly localizing in and penetrating throughout solid tumors in preclinical models, including those in the brain and pancreas. Combined with their limited normal tissue exposure due to their efficient elimination via the kidneys this provides CDCs with the potential to achieve greater therapeutic indexes. Our lead CDC, ELU001, an anti-Folate Receptor Alpha that is currently in IND-enabling studies, will be presented.

Speaker:

Gregory Adams, Ph.D.
Chief Scientific Officer
Elucida Oncology

View More Details +

Quantitative Modeling and Simulation to Drive Critical Decisions from Research through Clinical Trials
10am EST / 3pm GMT / 4pm CET

Quantitative Systems Pharmacology (QSP) is a mathematical modeling and engineering approach that aims to quantitatively integrate knowledge about therapeutics with an understanding of its mechanism of action in the context of human disease mechanisms. Several examples will be shown which highlight QSP efforts to accelerate the discovery and development of best-in-class therapeutics and impact critical decisions, in the continuum from preclinical exploration to clinical research.

Speaker:

John M. Burke, PhD
Co-founder, President and CEO
Applied BioMath

View More Details +

DAY 3 – WEDNESDAY, MARCH 3, 2021



Antibody-siRNA Conjugates
9am EST / 2pm GMT / 3pm CET

This presentation will provide an overview of the technology platform that enables the development of antibody-siRNA conjugates as well as provide an update on our myotonic dystrophy program.

Speaker:

Arthur Levin, Ph.D.
Chief Scientific Officer
Avidity Biosciences

View More Details +

Leveraging polyclonal antibody sequencing to get high affinity binders against tough targets
10am EST / 3pm GMT / 4pm CET

Rapid Novor is the world leader in protein sequencing using mass spectrometry, having sequenced thousands of monoclonal antibodies and proteins over the past 6 years. In 2020 they unveiled their latest service offering, polyclonal antibody protein sequencing which has enabled them to sequence the most abundant and high affinity monoclonal antibodies within the poly mix. With significant interest in the diagnostic and reagent antibody space the technology aims to solve problems for pre-clinical therapeutics groups, and diagnostic teams. Come see more about the use cases behind their technology in this webinar.

Speaker:

Anthony Stajduhar
Director of International Business Development
Rapid Novor Inc

View More Details +

Tackle Difficult Targets by Accessing Broad B Cell Diversity
11am EST / 4pm GMT / 5pm CET

Traditional hybridoma and phage display methods have shown limited success in delivering therapeutic antibodies against promising but difficult targets such as GPCRs and ion channels.

Patricia Odermatt will present case studies of how Genovac has overcome this challenge by leveraging their core genetic immunization technology and Berkeley Lights’ Beacon® optofluidic system to rapidly discover antibodies against challenging targets, such as GPCRs, from a variety of different animal species.

Dr. Anupam Singhal will then provide an introduction to the new Opto™ Plasma B Discovery 4.0 workflow that accelerates lead molecule discovery against difficult targets. He will demonstrate recovery of 1000s of hits by screening up to 100,000 plasma B cells, early down-selection of lead candidates by functional profiling, and sequencing and re-expression of >1,000 functionally-characterized antibodies, all in 1 week.

Speakers:

Patricia Odermatt, MSc.
Research Scientist, Single B cell Technology
Genovac Antibody Discovery

Anupam Singhal, PhD
Sr. Product Manager, Antibody Discovery
Berkeley Lights

View More Details +

REGISTER NOW – Please select the webcast(s) you wish to attend and enter your contact details



Day 1

Day 2

Day 3